Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
AssigneeArizona Board of Regents on Behalf of the University of Arizona, a body corporate
InventorsRobin Polt, Torsten A E Falk
Life of this patent
Estimating the term…
Abstract
A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC1 receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PD, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PD, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
Claims14
A pharmaceutical composition comprising a glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) in a pharmaceutically acceptable carrier, wherein leucine 1 of said glycosylated PACAP is replaced with serine, and wherein said serine is glycosylated, and wherein said glycosylated PACAP comprises the amino acid sequence of SEQ ID NO:4.
A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP), wherein the PACAP comprises the amino acid sequence of SEQ ID NO:3, and wherein leucine 1 of the PACAP is replaced with serine, and wherein said serine is glycosylated.
Dependencies are inferred from the claim text.